Literature DB >> 25160710

Cannabinoids for neuropathic pain.

Perry G Fine1, Mark J Rosenfeld.   

Abstract

Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse effects. The endocannabinoid system has been elucidated over the last several years, demonstrating a significant interface with pain homeostasis. Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions. This article reviews the history, pharmacologic development, clinical trials results, and the future potential of nonsmoked, orally bioavailable, nonpsychoactive cannabinoids in the management of neuropathic pain.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25160710     DOI： 10.1007/s11916-014-0451-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  79 in total

1.  The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism.

Authors:  L De Petrocellis; T Bisogno; M Maccarrone; J B Davis; A Finazzi-Agro; V Di Marzo
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

2.  Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.

Authors:  Michael Iskedjian; Basil Bereza; Allan Gordon; Charles Piwko; Thomas R Einarson
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

Review 3.  Cannabinoid receptors and pain.

Authors:  R G Pertwee
Journal:  Prog Neurobiol       Date:  2001-04       Impact factor: 11.685

4.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

5.  Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.

Authors:  Diana L Cichewicz; Erin A McCarthy
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

Review 6.  Cannabinoid type 2 receptor as a target for chronic - pain.

Authors:  Massimiliano Beltramo
Journal:  Mini Rev Med Chem       Date:  2009-01       Impact factor: 3.862

7.  Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons.

Authors:  Uma Anand; William R Otto; Daniel Sanchez-Herrera; Paul Facer; Yiangos Yiangou; Yuri Korchev; Rolfe Birch; Christopher Benham; Chas Bountra; Iain P Chessell; Praveen Anand
Journal:  Pain       Date:  2008-08-09       Impact factor: 6.961

8.  Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.

Authors:  Celia J A Morgan; H Valerie Curran
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

9.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

10.  Amygdala activity contributes to the dissociative effect of cannabis on pain perception.

Authors:  Michael C Lee; Markus Ploner; Katja Wiech; Ulrike Bingel; Vishvarani Wanigasekera; Jonathan Brooks; David K Menon; Irene Tracey
Journal:  Pain       Date:  2013-01       Impact factor: 6.961
View more
  13 in total

1.  An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain.

Authors:  Yong Fang Zhu; Katja Linher-Melville; Mohammad Javad Niazmand; Manu Sharma; Ayesha Shahid; Kan Lun Zhu; Natalka Parzei; Jesse Sidhu; Christeene Haj; Raphael Mechoulam; Gurmit Singh
Journal:  Br J Pharmacol       Date:  2020-03-08       Impact factor: 8.739

2.  Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Authors:  Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Neuropharmacology       Date:  2016-12-20       Impact factor: 5.250

Review 3.  Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Authors:  Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

4.  Cannabinoids and an anti-inflammatory diet for the treatment of neuropathic pain after spinal cord injury (The CATNP Study): study protocol for a randomized controlled trial.

Authors:  David J Allison; Alexandria Roa Agudelo; Brian C F Chan; David S Ditor; Eldon Loh
Journal:  Spinal Cord       Date:  2020-07-01       Impact factor: 2.772

Review 5.  Medical Cannabis for Neuropathic Pain.

Authors:  Gemayel Lee; Brittany Grovey; Tim Furnish; Mark Wallace
Journal:  Curr Pain Headache Rep       Date:  2018-02-01

6.  Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain.

Authors:  Wen S Sheng; Priyanka Chauhan; Shuxian Hu; Sujata Prasad; James R Lokensgard
Journal:  Pain Res Manag       Date:  2019-07-04       Impact factor: 3.037

7.  Pretreatment with AM1241 Enhances the Analgesic Effect of Intrathecally Administrated Mesenchymal Stem Cells.

Authors:  Junran Xie; Jinxuan Ren; Na Liu; Chengwei Wu; Dongju Xiao; Huanyu Luo; Jingxian Du
Journal:  Stem Cells Int       Date:  2019-09-10       Impact factor: 5.443

8.  Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models.

Authors:  Jasmine Siew Min Chia; Ahmad Akira Omar Farouk; Tengku Azam Shah Tengku Mohamad; Mohd Roslan Sulaiman; Hanis Zakaria; Nurul Izzaty Hassan; Enoch Kumar Perimal
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

9.  Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.

Authors:  Junran Xie; Dongju Xiao; Yun Xu; Jinning Zhao; Li Jiang; Xuming Hu; Yaping Zhang; Lina Yu
Journal:  Oncotarget       Date:  2016-02-09

10.  The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation.

Authors:  Dinesh Thapa; Elizabeth A Cairns; Anna-Maria Szczesniak; James T Toguri; Meggie D Caldwell; Melanie E M Kelly
Journal:  Cannabis Cannabinoid Res       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.